Erin Crane, MD, MPH

Reduce clinician burnout by delegating admin tasks to strong support teams and using AI dictation tools to streamline charting and protect personal time.

How HRD and BRCA results steer frontline ovarian cancer maintenance—niraparib vs olaparib—plus guidance on recurrence, surgery, and clinic efficiency.

Neoadjuvant chemotherapy increasingly matches upfront debulking outcomes, reducing extreme surgery risks while highlighting why patients still need access to R0 radical resection.

New data links PARP maintenance after recurrence to higher AML/MDS risk and shorter survival, pushing most use to frontline therapy.

Molecular profiling guides ovarian cancer maintenance: HRD and BRCA results steer PARP inhibitors, bevacizumab choices, and patient counseling.

The approved PARP inhibitor niraparib has been beneficial for patients with recurrent ovarian cancer, but new second-line restrictions for certain patients have led physicians to be more cautious when re-challenging these patients.